- Quotes
- Dashboard
- Chart
- Historical Prices
- Options
- News & PR
- News
- Market Currents
- Press Releases
- Coverage
- Cramer
- Top Analysts
- Business Intelligence
- Transcripts
- Events
- Key Developments
- Earnings
- History & Projected
- Consensus
- Peer Earnings
- Filings
- SEC Filings
- Annual Report
- Financials
- Income Statement
- Balance Sheet
- Cash Flow
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
CRIS Market Currents
more »
-
May 8 Curis (CRIS): Q1 EPS of $0.03 beats by $0.01. Revenue of $10.4M (+7719% Y/Y) beats by $1.2M. (PR)
Comment![Earnings, Healthcare]
CRIS in Focus
more »
CRIS Related Articles
more »
CRIS News
more »
-
at MarketWatch.com (Jun 14, 2011)
-
at MarketWatch.com (Apr 29, 2011)
-
at MarketWatch.com (Apr 6, 2011)
-
at MarketWatch.com (Apr 6, 2011)
-
at MarketWatch.com (Mar 21, 2011)
CRIS Press Releases and Filings
more »
-
GlobeNewswire (May 17, 2012)
-
GlobeNewswire (May 8, 2012)
-
GlobeNewswire (May 7, 2012)
-
GlobeNewswire (May 1, 2012)
-
GlobeNewswire (Apr 30, 2012)
CRIS Latest Transcript
more »
-
Fri, May 7, 2010Popular searches: drug, ASCO, debiopharm, gdc-0449, dose, also, patients, think, additional, believe.
CRIS Cramer
more »
Currently, there are no Cramer articles on CRIS.
CRIS Instablog posts
more »
CRIS vs. ETF Alternatives
Company Description
We are a drug discovery and development company that is committed to leveraging our innovative signaling pathway drug technologies in seeking to develop next generation targeted cancer therapies. Biological signaling pathways, also referred to as signaling pathways, are prominent regulators of... More
